|
1
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ohashi K, Maruvka YE, Michor F and Pao W:
Epidermal growth factor receptor tyrosine kinase
inhibitor-resistant disease. J Clin Oncol. 31:1070–1080. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Konig D, Prince SS and Rothschild SI:
Targeted therapy in advanced and metastatic non-small cell lung
cancer. An update on treatment of the most important actionable
oncogenic driver alterations. Cancers (Basel). 13:804–840. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bivona TG and Doebele RC: A framework for
understanding and targeting residual disease in oncogene-driven
solid cancers. Nat Med. 22:472–478. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lin A, Wei T, Meng H, Luo P and Zhang J:
Role of the dynamic tumor microenvironment in controversies
regarding immune checkpoint inhibitors for the treatment of
non-small cell lung cancer (NSCLC) with EGFR mutations. Mol Cancer.
18:1392019. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Loyher PL, Hamon P, Laviron M,
Meghraoui-Kheddar A, Goncalves E, Deng Z, Torstensson S, Bercovici
N, de Chanville CB, Combadière B, et al: Macrophages of distinct
origins contribute to tumor development in the lung. J Exp Med.
215:2536–2553. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bonde AK, Tischler V, Kumar S, Soltermann
A and Schwendener RA: Intratumoral macrophages contribute to
epithelial-mesenchymal transition in solid tumors. BMC Cancer.
12:352012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Mantovani A, Marchesi F, Malesci A, Laghi
L and Allavena P: Tumour-associated macrophages as treatment
targets in oncology. Nat Rev Clin Oncol. 14:399–416. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
De Palma M and Lewis CE: Macrophage
regulation of tumor responses to anticancer therapies. Cancer Cell.
23:277–286. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Mantovani A and Allavena P: The
interaction of anticancer therapies with tumor-associated
macrophages. J Exp Med. 212:435–445. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Jia Y, Li X, Jiang T, Zhao S, Zhao C,
Zhang L, Liu X, Shi J, Qiao M, Luo J, et al: EGFR-targeted therapy
alters the tumor microenvironment in EGFR-driven lung tumors:
Implications for combination therapies. Int J Cancer.
145:1432–1444. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wang DH, Lee HS, Yoon D, Berry G, Wheeler
TM, Sugarbaker DJ, Kheradmand F, Engleman E and Burt BM:
Progression of EGFR-mutant lung adenocarcinoma is driven by
alveolar macrophages. Clin Cancer Res. 23:778–788. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Garrido-Martin EM, Mellows TWP, Clarke J,
Ganesan AP, Wood O, Cazaly A, Seumois G, Chee SJ, Alzetani A, King
EV, et al: M1(hot) tumor-associated macrophages boost
tissue-resident memory T cells infiltration and survival in human
lung cancer. J Immunother Cancer. 8:e0007782020. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Xiao F, Liu N, Ma X, Qin J, Liu Y and Wang
X: M2 macrophages reduce the effect of gefitinib by activating
AKT/mTOR in gefitinib-resistant cell lines HCC827/GR. Thorac
Cancer. 11:3289–3298. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhang B, Zhang Y, Zhao J, Wang Z, Wu T, Ou
W, Wang J, Yang B, Zhao Y, Rao Z and Gao J: M2-polarized
macrophages contribute to the decreased sensitivity of EGFR-TKIs
treatment in patients with advanced lung adenocarcinoma. Med Oncol.
31:1272014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chung FT, Lee KY, Wang CW, Heh CC, Chan
YF, Chen HW, Kuo CH, Feng PH, Lin TY, Wang CH, et al:
Tumor-associated macrophages correlate with response to epidermal
growth factor receptor-tyrosine kinase inhibitors in advanced
non-small cell lung cancer. Int J Cancer. 131:E227–E235. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Gentek R, Molawi K and Sieweke MH: Tissue
macrophage identity and self-renewal. Immunol Rev. 262:56–73. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Mascia F, Lam G, Keith C, Garber C,
Steinberg SM, Kohn E and Yuspa SH: Genetic ablation of epidermal
EGFR reveals the dynamic origin of adverse effects of anti-EGFR
therapy. Sci Transl Med. 5:199ra1102013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ginhoux F and Guilliams M: Tissue-resident
macrophage ontogeny and homeostasis. Immunity. 44:439–449. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Xu-Vanpala S, Deerhake ME, Wheaton JD,
Parker ME, Juvvadi PR, MacIver N, Ciofani M and Shinohara ML:
Functional heterogeneity of alveolar macrophage population based on
expression of CXCL2. Sci Immunol. 5:eaba73502020. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Du J, Li G, Jiang L, Zhang X, Xu Z, Yan H,
Zhou Z, He Q, Yang X and Luo P: Crosstalk between alveolar
macrophages and alveolar epithelial cells/fibroblasts contributes
to the pulmonary toxicity of gefitinib. Toxicol Lett. 338:1–9.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Mukaida N, Nosaka T, Nakamoto Y and Baba
T: Lung macrophages: Multifunctional regulator cells for metastatic
cells. Int J Mol Sci. 20:1162018. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Li Z, Maeda D, Yoshida M, Umakoshi M,
Nanjo H, Shiraishi K, Saito M, Kohno T, Konno H, Saito H, et al:
The intratumoral distribution influences the prognostic impact of
CD68- and CD204-positive macrophages in non-small cell lung cancer.
Lung Cancer. 123:127–135. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Casanova-Acebes M, Dalla E, Leader AM,
LeBerichel J, Nikolic J, Morales BM, Brown M, Chang C, Troncoso L,
Chen ST, et al: Tissue-resident macrophages provide a
pro-tumorigenic niche to early NSCLC cells. Nature. 595:578–584.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Cotechini T, Atallah A and Grossman A:
Tissue-resident and recruited macrophages in primary tumor and
metastatic microenvironments: Potential targets in cancer therapy.
Cells. 10:9602021. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Strober W: Trypan blue exclusion test of
cell viability. Curr Protoc Immunol. 111:A3.B.1–A3.B.3. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhao BX, Wang J, Song B, Wei H, Lv WP,
Tian LM, Li M and Lv S: Establishment and biological
characteristics of acquired gefitinib resistance in cell line
NCI-H1975/gefinitib-resistant with epidermal growth factor receptor
T790M mutation. Mol Med Rep. 11:2767–2774. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Li M, Zhang Q, Liu L, Liu Z, Zhou L, Wang
Z, Yue S, Xiong H, Feng L and Lu S: The different clinical
significance of EGFR mutations in exon 19 and 21 in non-small cell
lung cancer patients of China. Neoplasma. 58:74–81. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Sun Xuerui WY, Jialin G and Li Mei:
Difference between LCGreen PLUS and EvaGreen in detecting EGFR
mutation with HRM. J Dalian Med Univ. 42:391–394. 2020.
|
|
30
|
R Core Team. R, . A language and
environment for statistical computing. R Foundation for Statistical
Computing; Vienna, Austria: ISBN 3-900051-07-0, URL. http://www.R–project.org/
|
|
31
|
Hakuno F and Takahashi SI: IGF1 receptor
signaling pathways. J Mol Endocrinol. 61:T69–T86. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ark AV, Cao J and Li X: TGF-β receptors:
In and beyond TGF-beta signaling. Cell Signal. 52:112–120. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Rotow J and Bivona TG: Understanding and
targeting resistance mechanisms in NSCLC. Nat Rev Cancer.
17:637–658. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Paez JG, Janne PA, Lee JC, Tracy S,
Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, et
al: EGFR mutations in lung cancer: Correlation with clinical
response to gefitinib therapy. Science. 304:1497–1500. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Batlle E and Massague J: Transforming
growth factor-β signaling in immunity and cancer. Immunity.
50:924–940. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Caja L, Dituri F, Mancarella S,
Caballero-Diaz D, Moustakas A, Giannelli G and Fabregat I: TGF-β
and the tissue microenvironment: Relevance in fibrosis and cancer.
Int J Mol Sci. 19:12942018. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Yu X, Buttgereit A, Lelios I, Utz SG,
Cansever D, Becher B and Greter M: The cytokine TGF-beta promotes
the development and homeostasis of alveolar macrophages. Immunity.
47:903–912. e9042017. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Wang H, Wang X, Li X, Fan Y, Li G, Guo C,
Zhu F, Zhang L and Shi Y: CD68(+)HLA-DR(+) M1-like macrophages
promote motility of HCC cells via NF-κB/FAK pathway. Cancer Lett.
345:91–99. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Yao Z, Fenoglio S, Gao DC, Camiolo M,
Stiles B, Lindsted T, Schlederer M, Johns C, Altorki N, Mittal V,
et al: TGF-beta IL-6 axis mediates selective and adaptive
mechanisms of resistance to molecular targeted therapy in lung
cancer. Proc Natl Acad Sci USA. 107:15535–15540. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Fukuoka M, Yoshioka K and Hohjoh H: NF-κB
activation is an early event of changes in gene regulation for
acquiring drug resistance in human adenocarcinoma PC-9 cells. PLoS
One. 13:e02017962018. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Wan L, Wang Y, Tang Y, Tan Y, He F, Zhang
Y, Yang K, Chen Z, Song C, Gu R, et al: Gefitinib-induced cutaneous
toxicities in brown norway rats are associated with macrophage
infiltration. Inflammation. 43:2137–2146. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Bukowski K, Kciuk M and Kontek R:
Mechanisms of multidrug resistance in cancer chemotherapy. Int J
Mol Sci. 21:32332020. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Anderson NR, Minutolo NG, Gill S and
Klichinsky M: Macrophage-based approaches for cancer immunotherapy.
Cancer Res. 81:1201–1208. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Kennedy LB and Salama AKS: A review of
cancer immunotherapy toxicity. CA Cancer J Clin. 70:86–104. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Im JS, Herrmann AC, Bernatchez C, Haymaker
C, Molldrem JJ, Hong WK and Perez-Soler R: Immune-modulation by
epidermal growth factor receptor inhibitors: Implication on
anti-tumor immunity in lung cancer. PLoS One. 11:e01600042016.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Hussaini S, Chehade R, Boldt RG, Raphael
J, Blanchette P, Vareki SM and Fernandes R: Association between
immune-related side effects and efficacy and benefit of immune
checkpoint inhibitors-A systematic review and meta-analysis. Cancer
Treat Rev. 92:1021342021. View Article : Google Scholar : PubMed/NCBI
|
